Natco Pharma launches breast cancer drug in the US
Drug maker Natco Pharma today said it has launched a generic version of anastrazole, used in treating breast cancer, in the US market.Updated: Jun 29, 2010 15:50 IST
Drug maker Natco Pharma on Tuesday said it has launched a generic version of anastrazole, used in treating breast cancer, in the US market.
The company has launched the drug in strength of 1 mg tablets in the US after getting US Food and Drugs Administration's nod, Natco Pharma said in a statement.
The product has been launched in the US through the company's marketing partners, it said but did not name the associates.
The estimated annual sales of anastrazole, which is patented by Astra Zeneca and sold as Arimidex, in the US is around $750 million.
"The company is confident of gaining a reasonable share of the market," Natco Pharma said.
Shares of Natco Pharma were trading at Rs 201.70 on the Bombay Stock Exchange on late afternoon trade, up 3.09 per cent from its previous close.
First Published: Jun 29, 2010 15:47 IST